Angiogenesis inhibitors in early development for gastric cancer. (2nd September 2017)
- Record Type:
- Journal Article
- Title:
- Angiogenesis inhibitors in early development for gastric cancer. (2nd September 2017)
- Main Title:
- Angiogenesis inhibitors in early development for gastric cancer
- Authors:
- Pinto, Mauricio P.
Owen, Gareth I.
Retamal, Ignacio
Garrido, Marcelo - Abstract:
- ABSTRACT: Introduction : Angiogenesis, or the generation of new blood vessels from pre-existent ones is a critical process for tumor growth and progression. Hence, the development of angiogenesis inhibitors with therapeutic potential has been a central focus for researchers. Most angiogenesis inhibitors target the Vascular Endothelial Growth Factor (VEGF) pathway, however a number of tyrosine kinase inhibitors (TKIs), immunomodulatory drugs (IMiDs) and inhibitors of the mammalian Target-Of-Rapamycin (mTOR) pathway also display antiangiogenic activity. Areas covered : Here we review the effectiveness of a variety of compounds with antiangiogenic properties in preclinical and clinical settings in gastric cancer (GC). Expert opinion : In coming years angiogenesis will remain as a therapeutic target in GC. To date, ramucirumab a monoclonal antibody that targets VEGFR2 is the most successful antiangiogenic tested in clinical studies, and it is now well established as a second-line therapy in GC. The arrival of precision medicine and the success of immune checkpoint inhibitors will increase the number of clinical trials using targeted agents like ramucirumab in combination with immune checkpoint inhibitors. A hypothetical working model that combines ramucirumab with immunotherapy is presented. Also, the impact of nanotechnology and a molecular subtype classification of GC are discussed
- Is Part Of:
- Expert opinion on investigational drugs. Volume 26:Number 9(2017)
- Journal:
- Expert opinion on investigational drugs
- Issue:
- Volume 26:Number 9(2017)
- Issue Display:
- Volume 26, Issue 9 (2017)
- Year:
- 2017
- Volume:
- 26
- Issue:
- 9
- Issue Sort Value:
- 2017-0026-0009-0000
- Page Start:
- 1007
- Page End:
- 1017
- Publication Date:
- 2017-09-02
- Subjects:
- Angiogenesis -- antiangiogenesis -- checkpoint inhibitors -- gastric cancer -- ramucirumab -- pembrolizumab -- nivolumab
Drugs -- Design -- Periodicals
Drugs, Investigational -- Bibliography
Drugs, Investigational -- Periodicals
615.1 - Journal URLs:
- http://informahealthcare.com/journal/eid ↗
http://www.ashley-pub.com/loi/eid ↗
http://informahealthcare.com ↗
http://puck.ashley-pub.com/vl=7681552/cl=12/nw=1/rpsv/journal/journal5_home.htm ↗ - DOI:
- 10.1080/13543784.2017.1361926 ↗
- Languages:
- English
- ISSNs:
- 1354-3784
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002953
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4444.xml